SCHEMBL2565724

SCHEMBL2565724

CCOC(=O)CN(C)P(=O)(OCC)OCC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA9 Q16790 1/20 0.47
MGAM O43451 1/20 0.41
GAA P10253 1/20 0.41
SI P14410 1/20 0.41
MGAM2 Q2M2H8 1/20 0.41
ALDH1A1 P00352 7/20 0.39
TRPA1 O75762 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
TSHR P16473 3/20 0.34
CYP1A2 P05177 1/20 0.34
ALOX15 P16050 2/20 0.33
ACHE P22303 1/20 0.33
LMNA P02545 1/20 0.33
HSD17B10 Q99714 1/20 0.33
CYP3A4 P08684 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2572508 0.80 MVD (0.42) CA12CA1CA2CA9GAA
SCHEMBL11569858 0.80 CA12 (0.50) CA12CA1CA2CA9MGAM
SCHEMBL10960614 0.74 L3MBTL1 (0.51) ALDH1A1SMN1; SMN2MEN1KMT2ATSHR
SCHEMBL12626769 0.73
SCHEMBL196815 0.72
SCHEMBL29597934 0.72 TSHR (0.46) GAAMEN1KMT2ATSHRACHE
SCHEMBL12589581 0.72 CA12 (0.59) CA12CA1CA2CA9MGAM
Hydrochloric Acid SCHEMBL8143027 0.70 CA12 (0.57) CA12CA1CA2CA9MGAM
Hydrochloric Acid SCHEMBL1876862 0.70 CA12 (0.57) CA12CA1CA2CA9MGAM
SCHEMBL8632964 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103819403-B For treating the disease relevant with fluid retention or salt over loading and the Compounds and methods for of disorder of gastrointestinal tract 阿德利克斯公司 2017-01-04 CN disclosed
CN-103819403-A Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders ARDELYX INC 2014-05-28 CN disclosed
EP-2384318-A2 COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS Ardelyx, Inc. (US) 2011-11-09 EP disclosed
WO-2010078449-A2 COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS ARDELYX, INC. (US) 2010-07-08 WO disclosed